This is an aggregated industry headline. Read the full story at FiercePharma →
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
Reporting a new miss in one indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in March.
By FiercePharma
· Aug 2, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Whether it's looming tariff threats or the rise of China, you need a truly global view to navigate today's bio…
The WeekBriefing
AbbVie’s Skyrizi generated $5.55 billion in second-quarter sales, nearly matching Humira’s best quarter. The r…
The WeekFiercePharma ↗
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed…